Short Communication - (2025) Volume 8, Issue 6
Received: 02-Nov-2025, Manuscript No. jbps-26-184405;
Editor assigned: 04-Nov-2025, Pre QC No. P-184405;
Reviewed: 18-Nov-2025, QC No. Q-184405;
Revised: 24-Nov-2025, Manuscript No. R-184405;
Published:
29-Nov-2025
Citation: Al-Mutairi, Farid A.. ”Mechanisms of Cancer Drug Resistance and Overcoming Them.” J Biomed Pharm Sci 08 (2025):557.
Copyright: © 2025 Al-Mutairi A. Farid This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.
Drug resistance in cancer chemotherapy represents a formidable obstacle, frequently leading to therapeutic failure and necessitating a comprehensive understanding of its underlying mechanisms. Diverse intrinsic and acquired processes contribute to this resistance, encompassing alterations in drug transport, enzymatic inactivation, target mutations, and adaptive signaling cascades within the tumor milieu. One prominent mechanism involves changes in drug accumulation. This can occur due to altered expression of influx and efflux transporters, which actively mediate the movement of chemotherapeutic agents into and out of cancer cells. For instance, overexpression of efflux pumps can drastically reduce intracellular drug concentrations to sub-therapeutic levels, rendering treatments ineffective. The tumor microenvironment (TME) itself is a critical determinant of drug response. Components such as cancer-associated fibroblasts, immune cells, and the extracellular matrix can secrete soluble factors that promote cancer cell survival, influence drug metabolism, and induce epigenetic changes, all of which foster chemoresistance. Therefore, understanding the intricate interactions within the TME is paramount for developing strategies to overcome resistance. Specific drug transporters, notably P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP), are well-characterized mediators of multidrug resistance (MDR). Their robust efflux activity is a direct cause of reduced intracellular drug accumulation, a major hurdle in treating a variety of cancers. Research efforts are actively pursuing inhibitors of these transporters to reverse MDR. Epigenetic modifications, including DNA methylation and histone modifications, offer another layer of complexity in the development of chemoresistance. These heritable changes in gene expression can alter the activity of genes involved in drug response pathways, such as drug transport, metabolism, DNA repair, and cell survival, without altering the underlying DNA sequence. The activation of pro-survival signaling pathways is a common strategy employed by cancer cells to evade apoptosis induced by chemotherapy. Pathways like PI3K/Akt and MAPK are frequently dysregulated, promoting cell survival and resistance to cell death signals triggered by therapeutic interventions. Targeting these aberrant signaling cascades is thus a key therapeutic objective. Enhanced DNA repair mechanisms represent a crucial survival advantage for cancer cells exposed to DNA-damaging chemotherapies. Upregulation of pathways like homologous recombination repair (HRR) and base excision repair (BER) allows cancer cells to efficiently repair drug-induced DNA lesions, thereby promoting their survival and contributing to treatment failure. Drug metabolism, primarily orchestrated by the cytochrome P450 (CYP) enzyme system, plays a significant role in determining the efficacy and toxicity of chemotherapeutic agents. Variations in CYP enzyme expression or activity can lead to accelerated drug inactivation or the generation of less potent metabolites, ultimately contributing to resistance. Tumor heterogeneity, a pervasive characteristic of malignant neoplasms, significantly complicates treatment strategies and fuels drug resistance. Intratumoral and intertumoral heterogeneity means that different cancer cell populations within a tumor may possess distinct genetic and phenotypic profiles, including varying susceptibility to therapies. Finally, the intricate interplay between the immune system and cancer chemotherapy significantly influences treatment outcomes. While some immune components within the TME can promote resistance, others can potentiate therapeutic effects. The strategic combination of immunotherapy with chemotherapy aims to leverage and modulate these immune interactions for enhanced tumor eradication.
Drug resistance is a significant challenge in cancer chemotherapy, leading to treatment failure, and it arises from a multitude of intrinsic and acquired cellular and molecular mechanisms. These mechanisms are multifaceted and often interconnected, contributing to the complex landscape of treatment resistance. Decreased drug accumulation is a primary driver of chemoresistance. This phenomenon is often mediated by altered expression and function of drug transporters, which regulate the influx and efflux of chemotherapeutic agents across the cell membrane. Overexpression of efflux pumps, such as P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP), actively extrudes drugs from cancer cells, reducing intracellular concentrations below therapeutic thresholds [3].
The tumor microenvironment (TME) plays a pivotal role in fostering drug resistance. It comprises a diverse array of non-cancerous cells, including cancer-associated fibroblasts (CAFs), immune cells, and endothelial cells, along with the extracellular matrix (ECM). These components secrete growth factors, cytokines, and chemokines that promote cancer cell survival, proliferation, and resistance to apoptosis. Moreover, the TME can influence drug metabolism and induce epigenetic alterations that further enhance chemoresistance [2].
Enhanced drug inactivation or metabolism can also contribute to chemoresistance. Cancer cells may upregulate enzymes responsible for drug detoxification or metabolize drugs into less active or inactive forms, thereby diminishing their therapeutic efficacy. The cytochrome P450 (CYP) enzyme system, for instance, is heavily involved in drug metabolism, and its altered activity can significantly impact chemotherapy response [8].
Mutations in drug targets represent another critical mechanism of resistance. When the molecular target of a chemotherapy drug undergoes genetic alterations, the drug may no longer be able to bind effectively or exert its intended effect. This is particularly relevant for targeted therapies and some conventional chemotherapeutics that act on specific cellular proteins or pathways. Activation of bypass signaling pathways allows cancer cells to circumvent the apoptotic signals induced by chemotherapy. Pro-survival pathways, such as the PI3K/Akt and MAPK signaling cascades, can become constitutively active in cancer cells, promoting cell survival and proliferation even in the presence of cytotoxic agents. Inhibiting these aberrant pathways is a key therapeutic strategy [5].
The tumor microenvironment's influence extends to promoting survival signals and immune evasion. The complex cellular and molecular interactions within the TME can create a protective niche for cancer cells, shielding them from both therapeutic agents and the host immune system. This immune evasion further complicates treatment outcomes [10].
Epigenetic modifications, including DNA methylation and histone modifications, are increasingly recognized as significant contributors to chemoresistance. These alterations can lead to stable changes in gene expression patterns, affecting the expression of genes involved in drug transport, metabolism, DNA repair, and cell survival. Reversing these epigenetic changes is an area of active research [4].
Enhanced DNA repair mechanisms are crucial for cancer cell survival when exposed to DNA-damaging chemotherapy. Cancer cells can upregulate various DNA repair pathways, such as homologous recombination repair (HRR) and base excision repair (BER), to efficiently repair drug-induced DNA damage, thus promoting resistance to these agents [6].
Autophagy, a cellular self-degradation process, plays a complex and often dual role in chemotherapy. While it can promote cancer cell survival under stress by recycling cellular components for energy, it can also contribute to cell death under certain circumstances. Dysregulation of autophagy can thus lead to chemoresistance, and modulating autophagy pathways is being explored as a therapeutic strategy [7].
Drug resistance in cancer chemotherapy is a major cause of treatment failure, driven by various intrinsic and acquired mechanisms. These include altered drug transport and accumulation due to transporter expression, enhanced drug inactivation or metabolism, mutations in drug targets, and the activation of pro-survival signaling pathways like PI3K/Akt and MAPK. The tumor microenvironment significantly contributes by promoting survival and immune evasion through interactions with stromal cells and immune components. Epigenetic modifications, such as DNA methylation and histone modifications, can alter gene expression related to drug response. Enhanced DNA repair mechanisms allow cancer cells to recover from drug-induced damage. Autophagy plays a complex role, sometimes promoting survival and other times cell death. Tumor heterogeneity, with diverse subclones possessing different resistance mechanisms, further complicates treatment. Understanding these mechanisms is crucial for developing strategies like combination therapies and novel drug designs to overcome resistance and improve patient outcomes.
None
None
